Compare Incyte Corporation (INCY) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs abrdn Physical Palladium Shares ETF — how do they compare? Incyte Corporation trades at $113.39 (market cap $22.85B), while abrdn Physical Palladium Shares ETF trades at $20.79 (market cap $586.03M). The key difference: Incyte Corporation is far larger — about 39× abrdn Physical Palladium Shares ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| INCY | PALL | |
|---|---|---|
Market Cap | $22.85B | $586.03M |
Volume | 1,927,029 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.93 | $37.18 |
52-Week Low | $83.80 | $20.30 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
PALL (Aberdeen Physical Palladium Shares ETF) trades at $20.30, down 4.47% with bearish technical signals from moving averages but bullish RSI readings. The ETF tracks palladium prices, which have declined 47% from January 2026 highs. Recent news highlights palladium's underperformance versus gold and silver, with some analysts viewing current levels as a buying opportunity given supply risks and industrial demand.
PALL presents a contrarian opportunity as palladium approaches technical support levels, though the metal faces headwinds from automotive sector volatility. The ETF's value depends entirely on palladium price movements rather than company fundamentals, creating pure commodity exposure with significant price volatility risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
